Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Aldred · SciRah

Researcher profile · Semantic Scholar

J. Aldred

Share profile

J. Aldred — researcher profile on SciRah

h-index: 19
Works: 80
Citations: 1,951

Most-cited papers

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
D. Jennings, S. Huntwork-Rodriguez, Anastasia G. Henry, J. Sasaki +35 more
2022Science Translational Medicine204 citations
Semantic Scholar
National randomized controlled trial of virtual house calls for Parkinson disease
Christopher A. Beck, Denise B. Beran, K. Biglan, Cynthia M. Boyd +48 more
2017Neurology189 citations Open access
Semantic Scholar
Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
M. Brys, L. Fanning, S. Hung, A. Ellenbogen +14 more
2019Movement Disorders178 citations Open access
Semantic Scholar
The past, present, and future of telemedicine for Parkinson's disease
Meredith A. Achey, J. Aldred, Noha Aljehani, B. Bloem +14 more
2014Movement Disorders167 citations Open access
Semantic Scholar
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
M. Schwarzschild, A. Ascherio, C. Casaceli, G. Curhan +100 more
2021Journal of the American Medical Association (JAMA)154 citations Open access
Semantic Scholar
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
T. Simuni, B. Fiske, Kalpana M. Merchant, C. Coffey +88 more
2020JAMA Neurology133 citations Open access
Semantic Scholar
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
J. Aldred, E. Freire-Álvarez, A. Amelin, A. Antonini +18 more
2023Neurological Therapeutics129 citations Open access
Semantic Scholar
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
M. Soileau, J. Aldred, K. Budur, Nahome Fisseha +14 more
2022Lancet Neurology129 citations
Semantic Scholar
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
A. Westenberger, V. Skrahina, T. Usnich, C. Beetz +155 more
2024Brain : a journal of neurology98 citations Open access
Semantic Scholar
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
A. Antonini, P. Odin, R. Pahwa, J. Aldred +7 more
2021Advances in Therapy78 citations Open access
Semantic Scholar
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
E. R. Dorsey, Meredith A. Achey, Christopher A. Beck, Denise B. Beran +49 more
2016Telemedicine journal and e-health62 citations Open access
Semantic Scholar
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
V. Fung, J. Aldred, M. P. Arroyo, F. Bergquist +18 more
2024Clinical Parkinsonism & Related Disorders54 citations Open access
Semantic Scholar
Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE.
J. Aldred, M. Anca-Herschkovitsch, A. Antonini, O. Bajenaru +14 more
2020Neurodegenerative Disease Management50 citations Open access
Semantic Scholar
DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
D. Standaert, J. Aldred, M. Anca-Herschkovitsch, P. Bourgeois +11 more
2021Movement Disorders Clinical Practice45 citations Open access
Semantic Scholar
Histopathology and computed tomography of age-associated degeneration of the equine temporohyoid joint.
R. Naylor, Justin D. Perkins, S. Allen, J. Aldred +3 more
2010Equine Veterinary Journal42 citations Open access
Semantic Scholar
Are high doses of carbidopa a concern? A randomized clinical trial in Parkinson’s disease
Lissa S. Brod, J. Aldred, J. G. Nutt
2012Movement Disorders32 citations Open access
Semantic Scholar
Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients
Lucas R. Sass, M. Khani, Jacob Romm, M. Schmid Daners +8 more
2020Fluids and Barriers of the CNS31 citations Open access
Semantic Scholar
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
K. Chaudhuri, N. Kovács, F. Pontieri, J. Aldred +13 more
2023Journal of Parkinson's Disease28 citations Open access
Semantic Scholar
Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
M. Burack, J. Aldred, C. Zadikoff, A. Vanagunas +4 more
2018Movement Disorders Clinical Practice23 citations Open access
Semantic Scholar
Post-traumatic shoulder movement disorders: A challenging differential diagnosis between organic and functional
S. Pandey, F. Nahab, J. Aldred, J. Nutt +1 more
2014Movement Disorders Clinical Practice18 citations Open access
Semantic Scholar
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
N. Kovács, L. Bergmann, M. Anca-Herschkovitsch, E. Cubo +11 more
2021Journal of Parkinson's Disease16 citations Open access
Semantic Scholar
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
Daryl Dekarske, G. Alva, J. Aldred, B. Coate +5 more
2020Journal of Parkinson's Disease15 citations Open access
Semantic Scholar
Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001)
M. Brys, A. Ellenbogen, L. Fanning, N. Penner +11 more
201811 citations
Semantic Scholar
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
J. Aldred, M. Bouchard, J. C. Martínez-Castrillo, M. Soileau +8 more
2025Movement Disorders Clinical Practice10 citations Open access
Semantic Scholar
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results
Wolfgang H. Jost, F. Bergquist, Andrew Evans, Sharon Hassin-Baer +17 more
2026Neurological Therapeutics9 citations Open access
Semantic Scholar
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
O. Mabrouk, B. Tichler, H. Arnold, E. Thoma +32 more
2026Nature Medicine8 citations
Semantic Scholar
Patients’ experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson’s disease
Michael J Soileau, Rajeev Kumar, Ashwini Parab, Triza Brion +7 more
2025Journal of Neurology7 citations Open access
Semantic Scholar
Deep Brain Stimulation Generator Replacement in End-Stage Parkinson Disease.
J. Carlson, Martha Palmer, A. Hoefer, Emily J Cox +3 more
2019World Neurosurgery5 citations
Semantic Scholar
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
R. Pahwa, J. Aldred, Niodita Gupta, Emi Terasawa +8 more
2022Neurological Therapeutics4 citations Open access
Semantic Scholar
Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation
T. Henriksen, J. C. Martínez-Castrillo, M. Huisman, S. Dhanani +8 more
2026Advances in Therapy3 citations Open access
Semantic Scholar
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
R. Pahwa, J. Aldred, A. Merola, Niodita Gupta +9 more
2022Clinical Parkinsonism & Related Disorders3 citations Open access
Semantic Scholar
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
J. Aldred, E. Freire-Álvarez, A. V. Amelin, A. Antonini +18 more
2023Neurological Therapeutics2 citations Open access
Semantic Scholar
Image-Guided Programming Tool for DBS Programming Used with a Multiple-Source, Constant-Current System Reduces Initial Programming Time (P4-11.012)
J. Aldred, Theresa Zesiewicz, Michael Okun, Juan Ramirez Castaneda +14 more
2023Monday, April 242 citations
Semantic Scholar
Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004)
Drew S. Kern, K. Dashtipour, J. Aldred, T. Kimber +9 more
2023Tuesday, April 252 citations
Semantic Scholar
Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial
Rajesh Pahwa, Eric Molho, Mark Lew, K. Dashtipour +39 more
2025Neurological Therapeutics1 citations Open access
Semantic Scholar
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials
Rajesh Pahwa, J. Aldred, M. Soileau, D. Standaert +13 more
2025Neurological Therapeutics1 citations Open access
Semantic Scholar
Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Motor Fluctuations in Parkinson’s Disease (P9-3.008)
V. Fung, F. Bergquist, S. Dhanani, M. Facheris +6 more
2024Neurology1 citations
Semantic Scholar
Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study (P9-3.006)
Michael J Soileau, J. Aldred, Z. Baldwin, Connie H. Yan +8 more
2024Neurology1 citations
Semantic Scholar
Real-World Outcomes in USA using DBS Systems with Directionality and Multiple Independent Current Control (P5-11.017)
M. Okun, K. Foote, Theresa Zesiewicz, Y. Bezchlibnyk +22 more
2023Monday, April 241 citations
Semantic Scholar
ID: 197800 Image-Guided Programming Reduces Initial DBS Programming Time in Parkinson's Disease Patients
J. Aldred, Theresa Zesiewicz, M. Okun, Juan Ramirez-Castaneda +14 more
2023Neuromodulation (Malden, Mass.)1 citations
Semantic Scholar
Long-term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson’s Disease Treated With Levodopa-Carbidopa Intestinal Gel: Final Analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study (P1-1.Virtual)
K. Chaudhuri, Norbert Kovács, F. Pontieri, J. Aldred +12 more
2022Neurology1 citations
Semantic Scholar
Safety and Efficacy of 24-Hour/Day Subcutaneous Infusion of Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease During a Phase 3 Study: 6-Month Interim Results (S16.009)
J. Aldred, B. Bergmans, Camille Carroll, E. F. Álvarez +7 more
2022Neurology1 citations
Semantic Scholar
A Retrospective Study Evaluating the Use of Anti-Parkinsonian Medications in Patients with Advanced Parkinson’s Disease Who Are Treated with Levodopa-Carbidopa Intestinal Gel and Deep Brain Stimulation: The PD-DUAL Study (2347)
J. Aldred, Fahd Amjad, Anita Johnson, P. Kukreja +8 more
2021Neurology1 citations
Semantic Scholar
Utilization of New Visualization Software for Deep Brain Stimulation Programming Using a Multiple-Source, Constant-Rechargeable System (1479)
J. Aldred, Theresa Zesiewicz, Y. Bezchlibnyk, Jonathan D. Carlson +2 more
2021Neurology1 citations
Semantic Scholar
Improvements in Dyskinesia with Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients in a ‘Real-World’ Study: Interim Results of the Multinational DUOGLOBE Study With up to 24 Months Follow-Up (1824)
J. Aldred, Norbert Kovács, F. Pontieri, D. Standaert +11 more
2020Neurology1 citations
Semantic Scholar
Levodopa-carbidopa intestinal gel treatment of motor fluctuations and dyskinesia in advanced Parkinson’s disease patients in a ‘real world’ setting: Interim results from the DUOGLOBE study
D. Standaert, J. Aldred, M. Anca-Herschkovitsch, Thomas L. Davis +9 more
2019Journal of Neurological Sciences1 citations
Semantic Scholar
Levodopa-Carbidopa Intestinal Gel for the Treatment of Motor Fluctuations and Dyskinesia in Patients with Advanced Parkinson’s Disease in a ‘Real World’ Setting: Results of an Interim Analysis of the Multinational Observational Long-term Study DUOGLOBE (S4.004)
D. Standaert, J. Aldred, M. Anca-Herschkovitsch, Thomas L. Davis +9 more
2019Neurology1 citations
Semantic Scholar
Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats
M. Burack, J. Aldred, C. Zadikoff, A. Vanagunas +4 more
2019Movement Disorders Clinical Practice1 citations Open access
Semantic Scholar
Does the Dose of Carbidopa Matter? A Randomized Clinical Trial in Parkinson's Disease (S02.006)
J. Nutt, J. Aldred, Lissa S. Brod
20121 citations
Semantic Scholar
Foslevodopa/Foscarbidopa Improves Pain in People With Advanced Parkinson’s Disease Who Have Uncontrolled Motor Fluctuations: Interim Results From the Real-World ROSSINI Study (P3-17.006)
J. Aldred, F. Bergquist, Andrew Evans, Sharon Hassin-Baer +14 more
2026Neurology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Kukreja×19
Invite
P. Kukreja — researcher profile on SciRah
M. Simu×10
Invite
M. Simu — researcher profile on SciRah
R. Iansek×9
Invite
R. Iansek — researcher profile on SciRah
M. Anca-Herschkovitsch×8
Invite
M. Anca-Herschkovitsch — researcher profile on SciRah

×7

Invite

W. Robieson — researcher profile on SciRah

Invite

A. Spiegel — researcher profile on SciRah

D. Standaert×7

Invite

D. Standaert — researcher profile on SciRah

Invite

M. Facheris — researcher profile on SciRah

Invite

F. Pontieri — researcher profile on SciRah

Invite

R. Pahwa — researcher profile on SciRah

Invite

L. Bergmann — researcher profile on SciRah

Thomas L. Davis×6

Invite

Thomas L. Davis — researcher profile on SciRah